Which blockbuster cancer biologics lose exclusivity, when biosimilars enter, and what the next wave – led by Keytruda's $25bn 2028 cliff – means for developers, payers and investors. Built on FDA Purple and Orange Book data.
$9.6bn
Market, 2025
Global oncology biosimilars, on a path to $17.5bn by 2030
76–90%
Wave 1 share
Biosimilar volume already captured on the first antibodies
$25bn+
Keytruda cliff
Revenue exposed at the 2028 U.S. loss of exclusivity
50–70%
Price discount
Typical ASP erosion at biosimilar steady state
Fourteen pages of analysis tracing the two-wave structure of oncology biosimilar competition, from the now-commoditised first wave to the immuno-oncology cliffs that define the rest of the decade.
A few of the visuals you'll find in the full PDF. Scroll across to preview the landscape infographic, the cliff timeline and the molecule-level analysis.
← Scroll to explore | download the full report below for the complete analysis
Tell us where to send it. We'll unlock the download immediately and email you a copy, plus a note when we publish new therapeutic-area editions.
Your download should begin automatically. If it doesn't, use the button below.
Download PDF againWe produce bespoke biosimilar and patent-cliff landscapes for any therapeutic area, on your target molecules, timelines and competitive set.
Immunology
Adalimumab, ustekinumab, the TNF and IL franchises
Request →Diabetes and Metabolic
Insulins, GLP-1s and the next biosimilar wave
Request →Ophthalmology
Aflibercept, ranibizumab and retinal biologics
Request →Neurology
MS and migraine biologics facing exclusivity loss
Request →Respiratory
Asthma and COPD biologics and inhaled portfolios
Request →Custom scope
Your molecule list, markets and timelines
Request →